Insight Molecular Diagnostics I (NASDAQ:IMDX)
| Market Cap | 102.68M-1.6% |
| Revenue (ttm) | 1.67M-60.8% |
| Net Income | -49.36M+22.2% |
| EPS | -1.52+56.3% |
| Shares Out | 32.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 590,488 |
| Open | 3.82 |
| Previous Close | 3.92 |
| Day's Range | 3.16 - 3.88 |
| 52-Week Range | 2.42 - 8.51 |
| Beta | 1.80 |
| Analysts | Buy |
| Price Target | 9.75(+206.60%) |
| Earnings Date | Nov 9, 2026 |
Insiders here have filed 3 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About IMDX
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IMDX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IMDX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IMDX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IMDX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IMDX Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Professional fees, legal, and outside services | $1.65M | 46.93% |
| Clinical trial and registry service fees | $641.00K | 18.28% |
| Facilities and insurance | $508.00K | 14.49% |
| Travel and entertainment | $288.00K | 8.21% |
| Marketing and advertising | $262.00K | 7.47% |
| Other income, net | $162.00K | 4.62% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IMDX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IMDX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IMDX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.86M |
| VXFVanguard Extended Market ETF | $972.39K |
| IWCiShares Micro-Cap ETF | $167.48K |
Estimated from each fund’s disclosed top holdings × AUM
IMDX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IMDX’s recent data — informational, not investment advice